Jose Rodriguez, MD
Undersea and Hyperbaric Medicine · McAllen, TXNPI 1346655669
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Smith+Nephew at 40.5% of the total. Reporting peaked in 2019 at $1,731 and has fallen 50.4% since, to $858 in 2025.
Across 304 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$3K
- Organogenesis Inc.$1K
- Urgo Medical North America, LLC$445
- Hydrofera LLC$426
- Kerecis Limited$343
- Melinta Therapeutics, LLC$274
- plus $2K from 22 others
What the payments were for
- Food & beverage$8,084100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 158 | $3,277 |
| Organogenesis Inc. | 28 | $1,004 |
| Urgo Medical North America, LLC | 19 | $445 |
| Hydrofera LLC | 20 | $426 |
| Kerecis Limited | 2 | $343 |
| Melinta Therapeutics, LLC | 3 | $274 |
| Aroa Biosurgery Incorporated | 5 | $237 |
| Reddress USA, Inc. | 2 | $231 |
| KCI USA, Inc. | 2 | $212 |
| Lifenet Health | 2 | $193 |
| Tactile Systems Technology Inc | 14 | $170 |
| Sechrist Industries Inc | 1 | $155 |
| AbbVie(2 entities) | 7 | $153 |
| Osiris Therapeutics Inc. | 17 | $140 |
| Pfizer | 1 | $118 |
| Reprise Biomedical, Inc. | 1 | $116 |
| Amniox Medical, Inc. | 8 | $104 |
| Misonix Inc | 1 | $95 |
| Cardiovascular Systems Inc. | 1 | $89 |
| Integra Lifesciences Corporation | 1 | $78 |
| Boston Scientific | 1 | $53 |
| Bard Peripheral Vascular, Inc. | 1 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Siemens Medical Solutions USA, Inc. | 1 | $28 |
| Next Science LLC | 3 | $23 |
| Bioventus LLC | 1 | $14 |
| Solventum Corporation | 1 | $14 |
| Advanced Oxygen Therapy Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$592
- Affinity$272
- PuraPly$240
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$221
- Kerecis Omega3 Wound$195
- Kerecis Omega3 SurgiClose$148
- PURAPLY WOUND MATRIX$147
- Apligraf$147
- TheraGenesis Wound Matrix$140
- SNAP$125
- Orbactiv$124
- HYDROFERA BLUE$119
- ELIQUIS$118
- Baxdela$116
- DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4$115
- UrgoK2$115
- ActiGraft$104
How this compares
$8,084 in reported general payments places this provider in the 80th percentile of 59 undersea and hyperbaric medicine providers in Texas.
See all undersea and hyperbaric medicine providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 83 | $56,176 |
| TrulicityDulaglutide | 16 | $16,547 |
| LinzessLinaclotide | 15 | $12,236 |
| EliquisApixaban | 20 | $12,195 |
| Gentamicin Sulfate | 82 | $3,687 |
| Atorvastatin Calcium | 98 | $1,333 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 12 | $1,094 |
| Pregabalin | 12 | $654 |
| Gabapentin | 40 | $559 |
| Ammonium Lactate | 20 | $553 |
| Losartan Potassium | 41 | $552 |
| Tamsulosin Hcl | 42 | $551 |
| Levothyroxine Sodium | 61 | $519 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $513 |
| Metoprolol Succinate | 42 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $3,277 | $56,17683 claims |
| AbbVieLinzess | $153 | $12,23615 claims |
| PfizerEliquis | $118 | $12,19520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 59 undersea and hyperbaric medicine providers in Texas.
Other undersea and hyperbaric medicine in McAllen
- Wade FarrowCollege Station$2.2M
- Timothy BumannAbilene$154K
- Heather AguirreSan Antonio$98K
- Ronald ScottFrisco$76K
- Andrew ApplewhiteDallas$46K
- Joseph WolcottLubbock$38K
- Noel OliveiraEdinburg$33K
- Maria AguinagaMission$18K
- Jayesh ShahSan Antonio$17K
- Marcus GitterleNew Braunfels$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.